Leukemia Clinical Trials in Pennsylvania

Showing 581-600 of 808 trials

Avelumab With Decitabine as First Line for AML Treatment of Patients With AML, Who Are Unfit for Intensive Chemotherapy

NCT03395873

The goal of this study is to test the safety of combination treatment with Avelumab and Decitabine in newly diagnosed AML patients who are unfit for intensive induction chemotherapy.

Acute Myeloid Leukemia

Milton S. Hershey Medical Center7 participantsStarted Jan 2018

Hershey, Pennsylvania, United States

NO_LONGER_AVAILABLE36 miles

Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy

NCT02312037

An expanded access/compassionate use protocol that allows access to Mylotarg for relapsed/refractory AML CD33 positive patients in the USA. Contact: B1761026@iconplc.com

CD33 Positive Acute Myelogenous Leukemia

Pfizer

Birmingham, Alabama, United States • Anchorage, Alaska, United States • Anchorage, Alaska, United States +139 more locations

Avelumab With Decitabine as First Line for AML Treatment of Patients With AML, Who Are Unfit for Intensive Chemotherapy

Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy

Leukemia Trials in Other Cities

Registry for Integrative Medicine Interventions Effectiveness

Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma

A Study of LY2510924 in Participants With Extensive-Stage Small Cell Lung Carcinoma

PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib

A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants

A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL

Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas

BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML)

Biomarkers for Post-Transplant Lymphoproliferative Disorders in Children

Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer

Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML

A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications

Comparability and Standardization of Controlled Allergen Challenge Facilities

Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia

A Study for Patients With Acute Leukemia

A Study of Advanced or Metastatic Non-small Cell Lung Cancer

Other Conditions in Pennsylvania